Immuno-oncology company Imugene (ASX:IMU) has appointed Dr Lesley Russell as a Non-Executive Director, a leading global pharmaceutical executive.
She has over 25 years experience in established and emerging pharmaceutical companies across multiple therapeutic areas including oncology and haematology.
Subject to shareholder approval, the Company will issue 25 million unlisted options expiring 3 years from the date of approval to be vested over 24 months to Dr Lesley Russell.
Following a Board review of its remuneration policies and to promote remuneration parity across the board, the Company has also agreed to issue 25 million unlisted options to its Non-Executive Directors, Charles Walker and Dr Axel Hoos with the same terms and conditions as Dr Lesley Russell, as a one off issue.
Shares in Imugene (ASX:IMU) are trading 5.88 per cent higher at $0.02.